Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-04-19 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
2023年度拟不进行利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the company's 2023 profit distribution plan, specifically stating that no profit distribution or capital reserve conversion to shares will be made. It includes details about the board and supervisory committee meetings approving the plan, references to regulatory guidelines from the China Securities Regulatory Commission, and notes that the plan will be submitted to the 2023 annual shareholders meeting for approval. The document is relatively short (1176 characters) and serves as a formal announcement of a dividend-related decision rather than a detailed financial report or full annual report. Therefore, it fits the category of Notice of Dividend Amount (DIV), as it announces the dividend distribution decision and related shareholder meeting procedures.
2024-04-19 Chinese
独立董事2023年度述职报告-何超
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of a company, covering the director's duties, attendance, communication with auditors, oversight of financial and internal control matters, and other governance-related activities during the year 2023. It includes specific references to the director's role in reviewing financial reports, internal controls, related party transactions, and compliance with regulatory requirements. The document is not a brief announcement or a certification but a substantive report on the director's annual work and observations. This fits the category of Board/Management Information (MANG), which includes announcements of changes or reports related to the company's board or senior management activities. The document is 3912 characters long, which is substantial but not a full annual report or financial statement. Therefore, the best classification is MANG with high confidence.
2024-04-19 Chinese
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee meetings approving the use of up to 300 million RMB of idle raised funds to purchase safe, liquid financial products with principal protection. The document includes background on the raised funds, investment purpose, risk control measures, and opinions from the supervisory board and sponsor institution. It is a formal announcement about the company's financing fund management activities rather than a financial report or audit. The document length is about 2,513 characters, relatively short and focused on a specific financing update. Therefore, it fits best under Capital/Financing Update (CAP).
2024-04-19 Chinese
独立董事2023年度述职报告-何前
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of a company, describing their duties, attendance at meetings, communication with auditors, oversight of financial reports, internal controls, and other governance matters for the year 2023. It includes specific references to the 2022 annual report, quarterly reports, internal control evaluation, audit firm engagement, and compliance with regulatory requirements. The content is focused on the independent director's annual duties and oversight rather than a general management report or a simple announcement. The document length is 4362 characters, which is relatively short but contains substantive content about the director's annual work and governance oversight, not just an announcement or certification. This fits best with the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities, including independent director reports. It is not an Annual Report (10-K) or Interim Report (IR) because it does not contain full financial statements or comprehensive financial performance data, but rather a governance-related report by an independent director. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司2023年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2023 annual verification of the deposit and use of raised funds by Lingkang Pharmaceutical Group Co., Ltd. It includes extensive financial data on the amounts raised in 2015 and 2020, the use and balance of these funds, management and storage of the funds, and compliance with regulatory requirements. The document also contains auditor opinions and sponsor institution verification, focusing specifically on the management and use of raised funds for the year 2023. This type of document is a specialized audit or verification report related to the use of raised capital, not a full annual report or earnings release. It is not a simple announcement or presentation but a comprehensive audit-related report on fundraising usage. Therefore, it fits best under the category Audit Report / Information (AR). FY 2023
2024-04-19 Chinese
关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (中审众环会计师事务所) for auditing services for the fiscal year 2024. It details the qualifications, independence, and fees related to the auditor, and mentions that the appointment is subject to approval at the 2023 annual shareholders meeting. The document does not contain any financial statements or audit reports themselves, but rather is a formal announcement about the auditor appointment process and related board and shareholder meeting approvals. The document length is 2589 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about auditor appointment rather than the audit report or annual report itself.
2024-04-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.